CASP8 and cancer: Our study showed that although ERK can be inhibited through simultaneous co-administration of these two kinds of anti-cancer agents, the formation of pro-caspase-8 homodimer was not increased, whereas pre-treatment with erlotinib could increase levels of this critical dimer.